Navigation Links
Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
Date:9/18/2007

LAKE FOREST, Calif., Sept. 18 /PRNewswire/ -- Worldwide markets of approved EGFr/HEr2 inhibitors grew by 34.2% during the first half of 2007, pushing sales to more than $3.2 billion, exceeding total sales reported in 2005. Hundreds of clinical trials are ongoing, aimed at expanding indications for these drugs and fueling continued rapid market growth. In addition to the seven marketed ErbB-pathway inhibitors, more than 50 novel agents targeting this pathway are in development.

"The ErbB Pathway in Cancer" is a series of comprehensive reports published in Future Oncology, New Medicine's premiere newsletter. Future Oncology provides analysis of critical issues in global cancer R&D, clinical practices, markets, and business and company developments. The series covers every aspect of the EGFr/HEr2 inhibitor marketplace, including:

-- Markets (USA and ROW) of approved drugs and forecasts

-- Treatment costs in the USA and ROW

-- Detailed ErbB pathway analyses

-- Associations of ErbB expression and mutations with specific indications

-- EGFr/HEr2-based diagnostic/theragnostic technologies and products

-- Detailed profiles of currently approved drugs

-- Comprehensive reviews of current use of approved drugs by indication

-- Comprehensive reviews of new indications of approved drugs

-- Protocols and interim and final results from clinical trials combining

approved ErbB pathway inhibitors with novel agents.

-- Detailed profiles of over 50 agents in development targeting the ErbB

pathway, including protocols and interim and final results from

hundreds of trials

This series, published in 5 parts, is available for purchase in electronic PDF or hard copy format.


'/>"/>
SOURCE New Medicine
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
4. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
5. MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
6. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
7. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
8. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
9. CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
10. Clinical Data on Eisais Oncology Pipeline to be Presented at ASCO Annual Meeting
11. Data from Rexahn Pharmaceuticals Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... DIEGO , Oct. 12, 2017 AVACEN ... recognized the company with their  2017 New Product Innovation Award ... based on extensive primary and secondary medical device market research ... Medical, through its first-to-market OTC, drug-free pain relief product, the ... unique approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... Calif. , Oct. 11, 2017  BioPharmX Corporation ... scientific team that developed an innovative way to use ... of the delivery of new drugs. ... Fall Clinical Dermatology Conference will show how researchers from ... Hospital, Harvard Medical School used a suite of imaging ...
(Date:10/11/2017)... CHICAGO , Oct. 11, 2017  Hill-Rom Holdings, ... its Aspen Surgical facility in Las Piedras, ... surgical scalpels and blades. ... confirmed that the facility sustained minor structural damage, temporary ... Hurricane Maria. Repairs have been completed, manufacturing operations have ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 2017 , ... First Healthcare Compliance (FHC), an industry leader ... range of technology and learning solutions at the 68th Annual American Healthcare Association ... held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, Nevada. ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized ... have expanded their existing home health joint venture through an agreement, effective October ... a joint venture home health company with Asante, delivering clinically integrated care, for ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... named one of Michigan’s 2017 Best and Brightest in Wellness® by Best and ... Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. ...
Breaking Medicine News(10 mins):